Analysts at UBS upgrade Health Management Associates Inc HMA from “neutral” to “buy.” The target price for HMA has been raised from $10 to $11.50.
HMA shares gained 3.69% to close at $9.55 on Friday.
More Analyst Ratings here
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
